47 related articles for article (PubMed ID: 31049998)
21. Estimating the effect of latent time-varying count exposures using multiple lists.
Won JY; Elliott MR; Sanchez-Vaznaugh EV; Sánchez BN
Biometrics; 2024 Jan; 80(1):. PubMed ID: 38386360
[TBL] [Abstract][Full Text] [Related]
22. Assumption Adequacy Averaging as a Concept to Develop More Robust Methods for Differential Gene Expression Analysis.
Pounds S; Rai SN
Comput Stat Data Anal; 2009 Mar; 53(5):1604-1612. PubMed ID: 20161327
[TBL] [Abstract][Full Text] [Related]
23. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.
Ahmed AA; Abdou AM
Curr Probl Cancer; 2019 Oct; 43(5):450-460. PubMed ID: 30670303
[TBL] [Abstract][Full Text] [Related]
25. Estimation of the volume under the receiver-operating characteristic surface adjusting for non-ignorable verification bias.
Zhang Y; Alonzo TA;
Stat Methods Med Res; 2018 Mar; 27(3):715-739. PubMed ID: 29338546
[TBL] [Abstract][Full Text] [Related]
26. The differential diagnostic value and clinical significance of serum HE4 in ovarian disease with elevated CA125.
Li W; Wang D
Arch Gynecol Obstet; 2020 May; 301(5):1219-1225. PubMed ID: 32266526
[TBL] [Abstract][Full Text] [Related]
27. Bayesian bootstrap estimation of ROC curve.
Gu J; Ghosal S; Roy A
Stat Med; 2008 Nov; 27(26):5407-20. PubMed ID: 18613217
[TBL] [Abstract][Full Text] [Related]
28. Bayesian nonparametric estimation of ROC surface under verification bias.
Zhu R; Ghosal S
Stat Med; 2019 Aug; 38(18):3361-3377. PubMed ID: 31049998
[TBL] [Abstract][Full Text] [Related]
29. Review of biomarker systems as an alternative for early diagnosis of ovarian carcinoma.
Srivastava A; Gupta A; Patidar S
Clin Transl Oncol; 2021 Oct; 23(10):1967-1978. PubMed ID: 33840014
[TBL] [Abstract][Full Text] [Related]
30. [Diagnostic and prognostic value of tumor markers, scores (clinical and biological) algorithms, in front of an ovarian mass suspected of an epithelial ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].
Bendifallah S; Body G; Daraï E; Ouldamer L
Gynecol Obstet Fertil Senol; 2019 Feb; 47(2):134-154. PubMed ID: 30733191
[TBL] [Abstract][Full Text] [Related]
31. HE4--a novel promising serum marker in the diagnosis of ovarian carcinoma.
Langmár Z; Németh M; Vleskó G; Király M; Hornyák L; Bösze P
Eur J Gynaecol Oncol; 2011; 32(6):605-10. PubMed ID: 22335019
[TBL] [Abstract][Full Text] [Related]
32. A comprehensive and comparative review of optimal cut-points selection methods for diseases with multiple ordinal stages.
Hua J; Tian L
J Biopharm Stat; 2020; 30(1):46-68. PubMed ID: 31250693
[TBL] [Abstract][Full Text] [Related]
33. Correcting for partial verification bias in diagnostic accuracy studies: A tutorial using R.
Arifin WN; Yusof UK
Stat Med; 2022 Apr; 41(9):1709-1727. PubMed ID: 35043447
[TBL] [Abstract][Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
